

Technology Appraisal Committee D Interests Register

Topic: Rimegepant for preventing episodic migraine [ID6275]

Publication Date: 05/07/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Professor David Meads	Committee member	Non-financial professional	University of Leeds has received funding from BMS and Janssen for research in an unrelated area.	20.12.2022 & 10.04.2023	N/A	It was agreed his declaration would not prevent Professor Meads from participating in discussion on this appraisal.
Dr Matt Bradley	Committee member	Financial	Dr Bradley is an employee of GSK, a listed competitor company for this appraisal.	15.12.2022 & 11.04.2023	N/A	As a direct conflict of interest Dr Bradley did not participate in discussions on this appraisal.
Dr Nathan Moore	Committee member	Personal	Dr Moore provided talks to another department within employing organisation, which was arranged by them, on unrelated topic. However, the other department arranged, without his prior knowledge, for Pfizer to provide lunch and a 5-minute talk on Paxlovid and	16.12.2022 & 03.04.2023	N/A	As a direct conflict of interest Dr Moore did not participate in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Rimegepant before providing my talk.			
Deborah Sloan	Patient expert	Financial	Deborah Sloan has received fees from Pfizer for being on a patient panel - giving insight into patient experience of migraine she confirmed she was not advising on any drug in particular but sharing personal experience on migraine as a whole. She also received fees for a presentation for Lundbeck - along the same lines - on her personal migraine experience.	11.10.2021	N/A	It was agreed that her declarations would not prevent Deborah from providing expert advice to the committee.
Dr Brendan Davies	Clinical expert	Professional	Dr Davies is a member of the ABN Headache & Pain advisory group and has contributed to prior headache treatment consultations with NICE and attended as a nominated ABN clinical expert as part of the TA 361	10.10.2021	N/A	It was agreed that his declarations would not prevent Dr Davies from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			assessment of Fremanezumab by NICE.			